A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

ClinicalTrials.gov ID: NCT03915379

Public ClinicalTrials.gov record NCT03915379. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-67371244 (Bispecific Antibody Targeting CD33 and CD3), in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Study identification

NCT ID: NCT03915379
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Janssen Research & Development, LLC; Industry
Enrollment: 68 participants

Conditions and interventions

Conditions

Interventions

JNJ-67571244 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 27, 2019
Primary completion: Mar 25, 2022
Completion: Mar 27, 2022
Last update posted: May 22, 2025

2019 – 2022

United States locations

U.S. sites: 9
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
Barbara Ann Karmanos Cancer Institute	Detroit	Michigan	48201	—
Hackensack University Medical Center	Hackensack	New Jersey	07601	—
NYU Hematology Associates	New York	New York	10016	—
Levine Cancer Institute, Carolinas HealthCare System	Charlotte	North Carolina	28204	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—
MD Anderson Cancer Center	Houston	Texas	77030	—
Fred Hutchinson Cancer Research Center	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03915379, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 22, 2025 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03915379 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →